Table 3 Predictors of progression-free survival

Age

1.046

1.004–1.089

0.031

Type of platinum compound used as the first-line (cisplatin vs carboplatin)

1.670

0.750–3.718

0.209

TTP of the first-line GP chemotherapy

0.951

0.885–1.022

0.175

Cycles of the first-line GP chemotherapy

0.947

0.834–1.076

0.404

TFI between GP and MVAC

0.991

0.943–1.042

0.735

 Bladder vs ureter or renal pelvis/ ureter or renal pelvis with bladder

1.525

0.782–2.975

0.216

 Bladder/ ureter or renal pelvis vs ureter or renal pelvis with bladder

1.735

0.806–3.733

0.159

 N (0 vs 1,2,3)

1.074

0.413–2.789

1.074

 N (0,1 vs 2,3)

0.712

0.354–1.431

0.340

 N (0,1,2 vs 3)

0.541

0.246–1.193

0.128

 M0 vs M1

1.335

0.670–2.658

0.411

 Lung

1.502

0.798–2.872

0.207

 Bone

1.207

0.631–2.310

0.569

 Liver

1.854

0.862–3.987

0.114

 Others

1.056

0.371–3.007

0.919

 Multi-organ metastasis (absence vs presence)

1.696

0.874–3.294

0.118

Hemoglobin

0.846

0.661–1.082

0.182

Absolute neutrophil count

1.000

1.000–1.000

0.823

Platelet count

1.001

0.997–1.004

1.001

eGFR

1.000

0.979–1.021

0.989

Serum bilirubin

0.529

0.077–3.630

0.517

Serum albumin

0.417

0.161–1.078

0.071

ECOG performance status (0 vs 1,2)

1.333

0.699–2.543

0.382

Response to first-line GP

2.520

1.245–5.015

0.010

Age

1.047

1.004–1.093

0.033

Response to first-line GP

2.500

1.228–5.098

0.012